WSK-V102C COVID-19 vaccine effectiveness against SARS-CoV-2 JN.1 symptomatic infection among adults 60 years and older: a prospective observational cohort study in Shaanxi Province, China, 2024.
Tang L, Hu W, Li Y, Guo C, Feng Z, Bai N, Wang R, Zhang S, Wang Y, Liu S, Wang X, Liu Q, Liu X, Rodewald LE, Wang F, Yin Z.
Tang L, et al.
BMC Public Health. 2025 Dec 5. doi: 10.1186/s12889-025-25750-1. Online ahead of print.
BMC Public Health. 2025.
PMID: 41350702
We evaluated WSK-V102C vaccine effectiveness (VE) against SARS CoV-2 JN.1 symptomatic infection among adults aged 60 years using an observational prospective cohort study. ...RESULTS: Among 6 313 participants meeting inclusion criteria, 3 216 received WSK-V10 …
We evaluated WSK-V102C vaccine effectiveness (VE) against SARS CoV-2 JN.1 symptomatic infection among adults aged 60 ye …